Clinical Trial Update: Study Evaluating the Analgesic Efficacy and Safety of ADL5859 in Participants With Rheumatoid Arthritis [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated the analgesic efficacy and safety of ADL5859 in rheumatoid arthritis; the study is completed and results were posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• ADL5859

Snippet

Sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: Rheumatoid Arthritis | Phase 2 | Status: COMPLETED | Results posted: 2015-07-01